Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients

Clinical Immunology

Volumn 124, Issue 3, 2007, Pages 284-293

  Frisullo, Giovanni ^a   Nociti, Viviana ^a,b   Iorio, Raffaele ^a   Katia Patanella, Agata ^a   Bianco, Assunta ^a   Caggiula, Marcella ^b   Sancricca, Cristina ^a   Tonali, Pietro Attilio ^a,b   Mirabella, Massimiliano ^a   Batocchi, Anna Paola ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Glucocorticoid; Multiple sclerosis; STAT 1; T bet

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID; LIPOCORTIN 5; METHYLPREDNISOLONE; STAT1 PROTEIN; TRANSCRIPTION FACTOR T BET;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; ANNEXIN A5; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DOWN-REGULATION; FEMALE; GLUCOCORTICOIDS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; T-BOX DOMAIN PROTEINS;

EID: 34547841656     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.05.011     Document Type: Article

References (28)

1. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
2. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 28 343 13 (2000) 938-952
3. Sellebjerg F., Barnes D., Filippini G., Midgard R., Montalban X., Rieckmann P., Selmaj K., Visser L.H., and Sorensen P.S. EFNS task force on treatment of multiple sclerosis relapses. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur. J. Neurol. 12 12 (2005) 939-946
4. Milligan N.M., Newcombe R., and Compston D.A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J. Neurol. Neurosurg. Psychiatry 50 5 (1987) 511-516
5. Nos C., Sastre-Garriga J., Borras C., Rio J., Tintore M., and Montalban X. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Mult. Scler. 10 4 (2004) 413-416
6. Kesselring J., Miller D.H., MacManus D.G., Johnson G., Milligan N.M., Scolding N., Compston D.A., and McDonald W.I. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J. Neurol. Neurosurg. Psychiatry 52 1 (1989) 14-17
7. Gold R., Buttgereit F., and Toyka K.V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J. Neuroimmunol. 117 (2001) 1-8
8. Sloka J.S., and Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult. Scler. 11 4 (2005) 425-432
9. Leussink V.I., Jung S., Merschdorf U., Toyka K.V., and Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 58 (2001) 91-97
10. Schmidt J., Gold R., Schonrock L., Zettl U.K., Hartung H.P., and Toyka K.V. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123 (2000) 1431-1441
11. Wilckens T., and De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol. Today 18 (1997) 418-428
12. Kisseleva T., Bhattacharya S., Braunstein J., and Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285 (2002) 1-24
13. Darnell Jr. J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
14. Schmitz J., Dahmen H., Grimm C., Gendo C., Muller-Newen G., Heinrich P.C., and Schaper F. The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction. J. Immunol. 164 2 (2000) 848-854
15. Wang J., Fathman J.W., Lugo-Villarino G., Scimone L., von Andrian U., Dorfman D., and Glimcher L.H. Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells. J. Clin. Invest. 116 (2006) 414-421
16. Lighvani A.A., Frucht D.M., Jankovic D., Yamane H., Aliberti J., Hissong B.D., Nguyen B.V., Gadina M., Sher A., Paul W.E., and O'Shea J.J. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 98 26 (2001) 15137-15142
17. Mullen A.C., High F.A., Hutchins A.S., Lee H.W., Villarino A.V., Livingston M.D., Kung A.L., Cereb N., Yao T.P., Yang S.Y., and Reiner S.L. Role of T-bet in commitment of Th1 cells before IL12-dependent selection. Science 292 (2001) 1907-1910
18. Frisullo G., Angelucci F., Caggiula M., Nociti V., Iorio R., Patanella A.K., Sancricca C., Mirabella M., Tonali P.A., and Batocchi A.P. pSTAT1, pSTAT3 and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J. Neurosci. Res. 84 5 (2006) 1027-1036
19. Boumpas D.T., Chrousos G.P., Wilder R.L., Cupps T.R., and Balow J.E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119 (1993) 1198-1208
20. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353 (2005) 1711-1723
21. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable?. Cell 93 (1998) 487-490
22. Liberman A.C., Refojo D., Druker J., Toscano M., Rein T., Holsboer F., and Arzt E. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J. (2007) (Jan 10; [Epub ahead of print])
23. Refojo D., Liberman A., Giacomini D., Carbia Nagashima C., Graciarena M., Echenique C., Paez Pereda M., Stalla G., Holsboer F., and Arzt E. Integrating Systemic Information at the molecular level: cross-talk between steroid receptors and cytokine signalling on different target cells. Ann. N. Y. Acad. Sci. 992 (2003) 196-204
24. Tantisira K.G., Hwang E.S., Raby B.A., Silverman E.S., Lake S.L., Richter B.G., Peng S.L., Drazen J.M., Glimcher L.H., and Weiss S.T. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc. Natl. Acad. Sci. U. S. A. 101 52 (2006) 18099-18104
25. Martinez-Caceres E.M., Barrau M.A., Brieva L., Espejo C., Barbera N., and Montalban X. Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin. Exp. Immunol. 127 1 (2002 Jan) 165-171
26. Takeda T., Kurachi H., Yamamoto T., Nishio Y., Nakatsuji Y., Morishige K.I., Miyake A., and Murata Y. Crosstalk between the interleukin-6-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL6 response element by IL6 and glucocorticoid. J. Endocrinol. 159 (1998) 323-330
27. Rogatsky I., and Ivashkiv L.B. Glucocorticoid modulation of cytokine signalling. Tissue Antigens 68 (2006) 1-12
28. Okuda Y., Apatoff B.R., and Posnet D.N. Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. J. Neuroimmunol. 171 (2006) 163-170